Aldeyra Therapeutics (ALDX) Treasury Shares (2013 - 2026)
Aldeyra Therapeutics' (ALDX) quarterly Treasury Shares came in at $89808.0 in Q1 2026, down 77.03% YoY from $391023.0 in Q1 2025, and down 67.28% on a QoQ basis from $274496.0 in Q4 2025.
Aldeyra Therapeutics (ALDX) Treasury Shares (2013 - 2026) Analysis & Trends
Aldeyra Therapeutics (ALDX) has 13 years of Treasury Shares data on file, last reported at $89808.0 in Q1 2026.
- Quarterly Treasury Shares fell 77.03% year-over-year to $89808.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $89808.0 (down 77.03% YoY) and the FY2025 annual result came in at $274496.0, down 49.26% from the prior year.
- Treasury Shares fell to $89808.0 in Q1 2026, from $274496.0 in the prior quarter.
- In the past five years, Treasury Shares ranged from a high of $1.2 million in Q1 2023 to a low of $89808.0 in Q1 2026.
- A 5-year average of $706455.0 and a median of $706446.0 in 2022 frame the typical range for Treasury Shares.
- Annual changes were most pronounced in 2022 — Treasury Shares soared 136.33% — and 2026, when it plunged 77.03%.
- Tracing ALDX's Treasury Shares over 5 years: stood at $1.2 million in 2022, then decreased by 20.27% to $944497.0 in 2023, then plunged by 42.72% to $540965.0 in 2024, then tumbled by 49.26% to $274496.0 in 2025, then sank by 67.28% to $89808.0 in 2026.
- The last three Treasury Shares figures came in at $89808.0 (Q1 2026), $274496.0 (Q4 2025), and $281273.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Treasury Shares (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 36.40 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 8.96 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 2.72 Mn |
| 10 | Aldeyra Therapeutics | 90.18 Mn | 90.18 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 89,808.00 |
| Jun 30, 2026 | 89,808.00 |
| Mar 31, 2026 | 89,808.00 |
| Mar 31, 2026 | 89,808.00 |
| Dec 31, 2025 | 274,496.00 |
| Dec 31, 2025 | 274,496.00 |
| Sep 30, 2025 | 281,273.00 |
| Sep 30, 2025 | 281,273.00 |
| Jun 30, 2025 | 364,567.00 |
| Jun 30, 2025 | 364,567.00 |
| Mar 31, 2025 | 391,023.00 |
| Mar 31, 2025 | 391,023.00 |
| Dec 31, 2024 | 540,965.00 |
| Dec 31, 2024 | 540,965.00 |
| Sep 30, 2024 | 604,009.00 |
| Sep 30, 2024 | 604,009.00 |
| Jun 30, 2024 | 732,056.00 |
| Jun 30, 2024 | 732,056.00 |
| Mar 31, 2024 | 732,056.00 |
| Mar 31, 2024 | 732,056.00 |